Trial · NCT02061085

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

NCT02061085, Phase 2, Completed, MedSIR; results first posted 2025-06-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment. Trials, record NCT02061085. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02061085

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
NCT number: NCT02061085
Status: Completed
Phases: Phase 2
Enrollment: 53 participants, actual
Lead sponsor: MedSIR
Conditions: Breast Neoplasm, Metastasis
Interventions: Eribulin
First posted: 2014-02-12
Last updated: 2025-06-08
Other registries' IDs: eudract:2012-004463-41
Results first posted: 2025-06-08

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Time to Progression	Through study completion, up to 27 months	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0)
Secondary	Duration of Response	Through study completion, up to 27 months	Duration of response
Secondary	Clinical Benefit Rate	Through study completion, up to 27 months
Secondary	Progression Free Survival	Through study completion, up to 27 months

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Time to Progression	Through study completion, up to 27 months	months	MEDIAN
SECONDARY	Duration of Response	Through study completion, up to 27 months	months	MEDIAN
SECONDARY	Clinical Benefit Rate	Through study completion, up to 27 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Progression Free Survival	Through study completion, up to 27 months	Months	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Time to Progression	Monotherapy Treatment With Eribulin	4.1	95% Confidence Interval 3.2 to 6.6	months
Duration of Response	Monotherapy Treatment With Eribulin	4.5	Full Range 2.1 to 20.9	months
Clinical Benefit Rate	Monotherapy Treatment With Eribulin	14		Participants
Progression Free Survival	Monotherapy Treatment With Eribulin	4.1	95% Confidence Interval 3.2 to 6.6	Months

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Monotherapy Treatment With Eribulin	53
Overall Study	COMPLETED	Monotherapy Treatment With Eribulin	45
Overall Study	NOT COMPLETED	Monotherapy Treatment With Eribulin	8

Source ClinicalTrials.gov

Adverse events27

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Neuropathy peripheral	Nervous system disorders	Monotherapy Treatment With Eribulin	10	53	10
other	Dry mouth	General disorders	Monotherapy Treatment With Eribulin	4	53	4
other	Nausea	Gastrointestinal disorders	Monotherapy Treatment With Eribulin	14	53	14
other	Constipation	Gastrointestinal disorders	Monotherapy Treatment With Eribulin	10	53	10
other	Anorexia and bulimia syndrome	Gastrointestinal disorders	Monotherapy Treatment With Eribulin	10	53	10
other	Abdominal pain	Gastrointestinal disorders	Monotherapy Treatment With Eribulin	7	53	7
other	Alopecia	Skin and subcutaneous tissue disorders	Monotherapy Treatment With Eribulin	18	53	18
other	Asthenia	Musculoskeletal and connective tissue disorders	Monotherapy Treatment With Eribulin	7	53	7
other	Musculoskeletal disorder	Musculoskeletal and connective tissue disorders	Monotherapy Treatment With Eribulin	7	53	7
other	Bone pain	Musculoskeletal and connective tissue disorders	Monotherapy Treatment With Eribulin	5	53	5

1 to 10 of 27Source ClinicalTrials.gov

See all 27 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Monotherapy Treatment With Eribulin	22	53
Total, other adverse events	Monotherapy Treatment With Eribulin	39	53
Total, serious adverse events	Monotherapy Treatment With Eribulin	11	53

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02061085

GET https://conductscience.org/api/trials/v1/NCT02061085/events?page=2

API reference For AI assistants